Mod­er­na’s ‘year of tran­si­tion’: Chang­ing gears from Covid-19 to RSV as vac­cine ap­proval date looms

Wrap­ping what it calls a “year of tran­si­tion,” Mod­er­na is fur­ther ex­pand­ing its com­mer­cial op­er­a­tions to­ward the po­ten­tial launch of its RSV vac­cine while down­siz­ing its Covid-19 ca­pa­bil­i­ties.

Ac­cord­ing to Mod­er­na’s full-year earn­ings re­port Thurs­day, its fourth-quar­ter sell­ing, gen­er­al and ad­min­is­tra­tive costs rose 25% to $470 mil­lion amid high­er per­son­nel, com­mer­cial and mar­ket­ing ex­pens­es. The RSV vac­cine is set to be Mod­er­na’s first tru­ly com­mer­cial prod­uct since its Covid-19 vac­cine Spike­vax was most­ly sold to gov­ern­ments at launch, al­though it shift­ed to the pri­vate sec­tor in the sec­ond half of last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER